Abstract 309P
Background
The American College of radiology proposed BI-RADS lexicon lacks defined rules which direct conversion of specific imaging features into a diagnostic category, results in a discrepancy of reporting. This study compares results from multilayer Perceptron neural network and a classification tree.
Methods
A total of 316 lesions with successive histological verification (221 malignant, 95 benign) were investigated. Six lesion criteria's were assessed by 2 readers in consensus. Classification analysis was performed using the chi-squared automatic interaction detection (CHAID) method. Results include the probability for malignancy for every descriptor combination in the classification tree. Simultaneously a multilayer Perceptron neural network was developed by using SPSS software.
Results
A classification tree incorporating 6 lesion descriptors with a depth of 4 ramifications (1- ADC values; 2 -root sign; 3- enhancement pattern; 4 - oedema) was calculated. Of all 316 lesions, 38 (40 %) and 212 (95.9 %) could be classified as benign and malignant with an accuracy above 95 %, respectively. Overall diagnostic accuracy was 79.1 %. The multilayer perceptron network segregated the lesions into training and testing sets in a ratio of 7:3. With a hyperbolic tangent activation function, there were six units of hidden layer and the model show a 20% and 17% incorrect predictions in the training in the testing sets. The diagnostic accuracy of malignant and benign lesions was 92% and 52 % in both the training and testing sets. The area under the curve of the ROC was .855. The order of importance of synaptic weights calculated from the model were ADC ( 0.257), Internal enhancement (0.233), ROOT SIGN (0.175), Margins (0.138), Curve type (0.138), edema (0.038) and mass / non mass (0.021).
Conclusions
The classification algorithm correctly classified 95 % malignant lesions with accuracy above 95 %. The neural network model showed good results on internal validation and revealed ADC to be the most significant parameter with the least importance to morphological classification into mass and non-mass lesions. Also, the dynamic contrast curve patterns were more significant than margins.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Rajiv Gandhi Cancer Institute and Research Center.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
393P - Clinical characteristics and prognosis of patients with pulmonary mucoepidermoid carcinoma: A SEER-based analysis
Presenter: Lingxiao Qiu
Session: e-Poster Display Session
394P - Apatinib plus etoposide capsules as third-line or further-line treatment for extensive stage small cell lung cancer patients: A multicenter, single arm, phase II clinical trial
Presenter: Zhen He
Session: e-Poster Display Session
395P - Afatinib in Asian and non-Asian patients (pts) with EGFR mutation positive (EGFRm+) NSCLC harboring major uncommon mutations
Presenter: James Chih-Hsin Yang
Session: e-Poster Display Session
396P - Efficacy and safety of S-1 in elderly patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy: A subgroup analysis of the EAST-LC
Presenter: James Chih-Hsin Yang
Session: e-Poster Display Session
397P - A phase I cohort expansion trial of OBI-833 in non-small cell lung cancer patients
Presenter: Ching-Liang Ho
Session: e-Poster Display Session
398P - Real-world mechanism of crizotinib-resistance in MET exon 14 skipping mutations non-small-cell lung cancer using next generation sequencing: A multicenter study
Presenter: Dong Wang
Session: e-Poster Display Session
399P - Real-world insights into patients (pts) with advanced NSCLC and MET alterations
Presenter: Marisa Bittoni
Session: e-Poster Display Session
400P - Sequential afatinib and osimertinib in real-world EGFR mutation positive (EGFRm+) NSCLC: Final analysis of Asian patients in the GioTag study
Presenter: Maximilian J. Hochmair
Session: e-Poster Display Session
401P - A prospective, phase II trial of low-dose afatinib monotherapy for patients with EGFR, mutation-positive, non-small cell lung cancer (TORG1632)
Presenter: Satoshi Igawa
Session: e-Poster Display Session
402P - Efficacy and safety of sintilimab plus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC)
Presenter: Zhehai Wang
Session: e-Poster Display Session